1. Scrip
  2. >>Archive

Ron Long resigns from Medivir as Maris Hartmanis made CEO

 
• By Gemma Sharman

Dr Maris Hartmanis, who joined Medivir on 1 September as deputy CEO and COO (scripintelligence.com, 1 September 2011), has been appointed the company's president and CEO. He will replace Ron Long who has been president and CEO of Medivir since 2009. Mr Long has resigned as CEO and a Medivir board member, following consultation with the board. Dr Hartmanis was appointed CEO of BioPhausia in 2010, a company which was recently acquired by Medivir.

Dr Maris Hartmanis, who joined Medivir on 1 September as deputy CEO and COO (scripintelligence.com, 1 September 2011), has been appointed the company's president and CEO. He will replace Ron Long who has been president and CEO of Medivir since 2009. Mr Long has resigned as CEO and a Medivir board member, following consultation with the board. Dr Hartmanis was appointed CEO of BioPhausia in 2010, a company which was recently acquired by Medivir.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

ASCO: AstraZeneca Changes Management Of Breast Cancer Resistance With SERENA-6

 
• By Mary Jo Laffler

AstraZeneca presented data from the SERENA-6 trial that experts said could represent a significant change in how HR+/HER2- breast cancer is treated.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: a preview of major ASCO readouts; Roivant stays patient in deals; Lilly diversifies pain pipeline with SiteOne acquisition; Nucala gets US COPD nod; and women in Indian pharma.

ASCO: Rusfertide Inches Toward FDA Filing With Positive 32-Week Data

 
• By Alaric DeArment

Takeda/Protagonist are awaiting 52-week data to confirm the results from the VERIFY trial of the drug in polycythemia vera.